218 related articles for article (PubMed ID: 27158246)
1. Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.
Brunetti L; Sanchez-Catanese B; Kagan L; Wen X; Liu M; Buckley B; Luyendyk JP; Aleksunes LM
Thromb J; 2016; 14():10. PubMed ID: 27158246
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
3. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
Martin JL; Esmaeili H; Manuel RC; Petrini M; Wiebe S; Maas H
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):399-406. PubMed ID: 29695165
[TBL] [Abstract][Full Text] [Related]
5. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
Blair HA; Keating GM
Drugs; 2017 Mar; 77(3):331-344. PubMed ID: 28185082
[TBL] [Abstract][Full Text] [Related]
7. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Skripka A; Sychev D; Bochkov P; Shevchenko R; Krupenin P; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):151-156. PubMed ID: 32215878
[TBL] [Abstract][Full Text] [Related]
8. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.
Šinigoj P; Malmström RE; Vene N; Rönquist-Nii Y; Božič-Mijovski M; Pohanka A; Antovic JP; Mavri A
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):323-9. PubMed ID: 25981948
[TBL] [Abstract][Full Text] [Related]
10. An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma.
Amiral J; Dunois C; Amiral C; Seghatchian J
Transfus Apher Sci; 2016 Jun; 54(3):428-37. PubMed ID: 27216543
[TBL] [Abstract][Full Text] [Related]
11. Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation.
Matsuda S; Imazu T; Kimura R; Nakamura M; Matsumoto A; Murakami T; Maeda Y
Ther Drug Monit; 2016 Dec; 38(6):670-676. PubMed ID: 27559839
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
14. Hemopericardium in a patient treated with dabigatran etexilate.
Barton CA; McMillian WD; Raza SS; Keller RE
Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation.
Lin SY; Tang SC; Kuo CH; Tsai LK; Yeh SJ; Shen LJ; Jeng JS
J Formos Med Assoc; 2019 Jul; 118(7):1154-1160. PubMed ID: 30581104
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of dabigatran peak and trough concentration in adults.
Ng JW; Mohd Tahir NA; Chin PKL; Makmor-Bakry M; Mohd Saffian S
Br J Clin Pharmacol; 2022 Oct; 88(10):4443-4459. PubMed ID: 35665523
[TBL] [Abstract][Full Text] [Related]
18. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Blommel ML; Blommel AL
Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
[TBL] [Abstract][Full Text] [Related]
20. Rash associated with dabigatran etexilate.
To K; Reynolds C; Spinler SA
Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
